Malabre Richard C
Known title: Chief Accounting OfficerCIK: 0002007730
Associated companies
Transaction History
| AKBA | ▼ Sell | Open Market | 36,142 | $50K | 2/2/2026 | View on chart |
| AKBA | ▼ Sell | Open Market | 13,382 | $19K | 2/2/2026 | View on chart |
| AKBA | ▲ Buy | Grant | 79,000 | $0 | 1/30/2026 | View on chart |
| AKBA | ▲ Buy | Option Exercise | 15,000 | $25K | 6/9/2025 | View on chart |
| AKBA | ▼ Sell | Open Market | 15,000 | $60K | 6/9/2025 | View on chart |
| AKBA | ▼ Sell | Open Market | 13,334 | $47K | 6/4/2025 | View on chart |
| AKBA | ▼ Sell | Open Market | 30,202 | $63K | 2/3/2025 | View on chart |
| AKBA | ▲ Buy | Grant | 85,000 | $0 | 1/31/2025 | View on chart |
| AKBA | ▲ Buy | Grant | 223,950 | $0 | 1/31/2024 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
September 26, 2026
AKBA sees no direct news updates this week
In the past week, there were no company‑specific announcements for Akebia Therapeutics (AKBA). The only notable filing was SCYNEXIS appointing Dr. Steven K. Burke to its board, which does not involve AKBA. As a result, there is little new information to affect AKBA’s market perception at this time.
AKBA sees no direct news updates this week. In the past week, there were no company‑specific announcements for Akebia Therapeutics (AKBA). The only notable filing was SCYNEXIS appointing Dr. Steven K. Burke to its board, which does not involve AKBA. As a result, there is little new information to affect AKBA’s market perception at this time.